Quidditas developed a novel genome editing platform which permits an absolute genetic recombination.
Quidditas has raised €2.6M across 1 funding round from 5 investors, most recently a round in May 2025. Based in Liège, France; active in Healthtech. Data as of 6 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-05-12 | Other | €2.6M |
| Business Angels,family businesses,iXLife Capital,Key Ventures,the Ministry of Research in Wallonia |
| View deal → |
